Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$4.30 +3.1%	$4.11	$1.89 ▼ $5.82	$1.25B	0.65	5.67 million shs	4.11 million shs
ADCT ADC Therapeutics	$3.11 -0.2%	$2.99	$1.05 ▼ $3.97	$349.87M	1.92	713,444 shs	464,616 shs
AMPH Amphastar Pharmaceuticals	$29.66 +0.1%	$24.01	$20.39 ▼ $53.96	$1.38B	0.76	634,017 shs	491,388 shs
VERA Vera Therapeutics	$22.61 +2.3%	$22.11	$18.53 ▼ $51.61	$1.41B	1.17	1.49 million shs	2.13 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-2.80%	-8.87%	-19.03%	+108.50%	+60.38%
ADCT ADC Therapeutics	-0.32%	+0.49%	-1.11%	+40.94%	+8.95%
AMPH Amphastar Pharmaceuticals	-2.34%	-2.82%	+39.78%	+22.40%	-35.64%
VERA Vera Therapeutics	+0.14%	+0.59%	-3.03%	+12.58%	-45.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.2902 of 5 stars	3.5	1.0	0.0	2.3	3.3	0.0
ADCT ADC Therapeutics	2.1569 of 5 stars	3.5	1.0	0.0	3.1	0.8	0.6
AMPH Amphastar Pharmaceuticals	3.2293 of 5 stars	1.3	1.0	3.7	2.6	4.2	1.3
VERA Vera Therapeutics	3.8211 of 5 stars	4.5	3.0	0.0	2.8	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	3.00	Buy	$8.00	86.05% Upside
ADCT ADC Therapeutics	3.00	Buy	$7.75	149.60% Upside
AMPH Amphastar Pharmaceuticals	2.50	Moderate Buy	$31.50	6.20% Upside
VERA Vera Therapeutics	2.90	Moderate Buy	$63.00	178.64% Upside

Current Analyst Ratings Breakdown

Latest ADCT, AMPH, VERA, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/12/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$36.00
8/8/2025	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
8/8/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $25.00
8/7/2025	VERA Vera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$56.00 ➝ $53.00
8/4/2025	VERA Vera Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Peer Perform
7/14/2025	ABCL AbCellera Biologics	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
7/7/2025	ABCL AbCellera Biologics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	ABCL AbCellera Biologics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	44.57	N/A	N/A	$3.37 per share	1.28
ADCT ADC Therapeutics	$70.84M	4.93	N/A	N/A	($1.77) per share	-1.75
AMPH Amphastar Pharmaceuticals	$731.97M	1.88	$4.89 per share	6.06	$16.29 per share	1.82
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$7.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.55	N/A	N/A	N/A	-511.88%	-16.17%	-12.24%	11/3/2025 (Estimated)
ADCT ADC Therapeutics	-$157.85M	-$1.57	N/A	N/A	N/A	-220.00%	N/A	-53.73%	11/6/2025 (Estimated)
AMPH Amphastar Pharmaceuticals	$159.52M	$2.67	11.11	9.02	N/A	18.64%	20.76%	9.68%	11/5/2025 (Estimated)
VERA Vera Therapeutics	-$152.15M	-$3.58	N/A	N/A	N/A	N/A	-46.70%	-39.46%	11/6/2025 (Estimated)

Latest ADCT, AMPH, VERA, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	-$0.50	-$0.14	-$0.50	$17.82 million	$18.84 million
8/7/2025	Q2 2025	ABCL AbCellera Biologics	-$0.17	-$0.12	+$0.05	-$0.12	$7.55 million	$17.08 million
8/5/2025	Q2 2025	VERA Vera Therapeutics	-$0.82	-$1.20	-$0.38	-$1.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	11.07	11.07
ADCT ADC Therapeutics	N/A	4.93	4.66
AMPH Amphastar Pharmaceuticals	0.80	3.29	2.21
VERA Vera Therapeutics	0.16	17.03	17.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
ADCT ADC Therapeutics	41.10%
AMPH Amphastar Pharmaceuticals	65.09%
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
ADCT ADC Therapeutics	5.40%
AMPH Amphastar Pharmaceuticals	27.50%
VERA Vera Therapeutics	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.83 million	212.47 million	Optionable
ADCT ADC Therapeutics	310	112.50 million	106.42 million	Optionable
AMPH Amphastar Pharmaceuticals	2,028	46.49 million	33.71 million	Optionable
VERA Vera Therapeutics	40	63.82 million	53.42 million	Optionable

ADCT, AMPH, VERA, and ABCL Headlines

Recent News About These Companies

19,597 Shares in Vera Therapeutics, Inc. $VERA Acquired by Fox Run Management L.L.C.

August 21 at 4:08 AM | marketbeat.com

Lord Abbett & CO. LLC Has $3.57 Million Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

August 19 at 5:18 AM | marketbeat.com

Can Vera Therapeutics’ (VERA) Widening Losses Challenge Its Path to Sustainable Growth?

August 19 at 5:07 AM | finance.yahoo.com

Deutsche Bank AG Purchases 82,483 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

August 15, 2025 | marketbeat.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $63.00 Average Price Target from Analysts

August 12, 2025 | americanbankingnews.com

JPMorgan Chase & Co. Cuts Vera Therapeutics (NASDAQ:VERA) Price Target to $53.00

August 10, 2025 | americanbankingnews.com

Cantor Fitzgerald Analysts Lower Earnings Estimates for VERA

August 10, 2025 | americanbankingnews.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 10, 2025 | marketbeat.com

Lifesci Capital Issues Negative Forecast for VERA Earnings

August 10, 2025 | americanbankingnews.com

FY2025 EPS Estimates for VERA Cut by Cantor Fitzgerald

August 9, 2025 | marketbeat.com

HC Wainwright Has Negative Estimate for VERA Q3 Earnings

August 9, 2025 | marketbeat.com

What is Lifesci Capital's Forecast for VERA Q3 Earnings?

August 9, 2025 | marketbeat.com

JPMorgan Chase & Co. Issues Pessimistic Forecast for Vera Therapeutics (NASDAQ:VERA) Stock Price

August 8, 2025 | marketbeat.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 8, 2025 | globenewswire.com

Vera Therapeutics Signs New Sales Agreement with TD Securities

August 8, 2025 | theglobeandmail.com

Q3 Earnings Forecast for Vera Therapeutics Issued By Wedbush

August 8, 2025 | marketbeat.com

Vera Therapeutics (VERA) to Release Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA) Posts Earnings Results, Misses Estimates By $0.38 EPS

August 6, 2025 | marketbeat.com

Vera (VERA) Q2 Net Loss Widens 127%

August 6, 2025 | fool.com

Vera Therapeutics (NASDAQ:VERA) Shares Gap Down - What's Next?

August 5, 2025 | marketbeat.com

Wolfe Research Downgrades Vera Therapeutics (VERA)

August 5, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ADCT, AMPH, VERA, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$4.30 +0.13 (+3.12%)

Closing price 04:00 PM Eastern

Extended Trading

$4.32 +0.03 (+0.58%)

As of 07:56 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ADC Therapeutics NYSE:ADCT

$3.10 -0.01 (-0.16%)

Closing price 03:59 PM Eastern

Extended Trading

$2.90 -0.20 (-6.44%)

As of 07:37 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Amphastar Pharmaceuticals NASDAQ:AMPH

$29.66 +0.04 (+0.14%)

Closing price 04:00 PM Eastern

Extended Trading

$29.66 0.00 (0.00%)

As of 04:20 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Vera Therapeutics NASDAQ:VERA

$22.61 +0.51 (+2.31%)

Closing price 04:00 PM Eastern

Extended Trading

$22.61 0.00 (0.00%)

As of 07:37 PM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time